Qihan Biotech Co. Ltd announced today that it has raised an additional $67 million in Series A++ financing. With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.

In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV).

On October 23, 2019, Dr. George Church visited Qihan, and he learned about the team’s research progress and gave a scientific speech on cutting-edge gene-editing technology.